



PATENT
Docket No. GZ 2096.00

5041
AB3

DECLARATION FOR UTILITY PATENT APPLICATION

AS A BELOW-NAMED INVENTOR, WE HEREBY DECLARE THAT:

Our residence, post office address, and citizenship are as stated below next to our names.

We believe we are the original, first and joint inventors of the subject matter which is claimed and for which a patent is sought on the invention entitled: **Method To Identify Antibody Targets** the specification of which is attached hereto unless the following box is checked:

was filed on September 18, 2001 as United States Application Serial No. 09/955,656.

WE HEREBY STATE THAT WE HAVE REVIEWED AND UNDERSTAND THE CONTENTS OF THE ABOVE-IDENTIFIED SPECIFICATION, INCLUDING THE CLAIMS, AS AMENDED BY ANY AMENDMENT REFERRED TO ABOVE.

We acknowledge the duty to disclose information which is material to the patentability as defined in 37 C.F.R. § 1.56.

We hereby claim foreign priority benefits under 35 U.S.C. § 119(a)-(d) or § 365(b) of any foreign application(s) for patent or inventor's certificate, or § 365(a) of any PCT International application which designated at least one country other than the United States listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate, or PCT International application having a filing date before that of the application on which priority is claimed:

Application No.	Country	Date of Filing (day/month/year)	Priority Claimed?
			<input type="checkbox"/> Yes <input type="checkbox"/> No

We hereby claim benefit under 35 U.S.C. § 119(e) of any United States provisional application(s) listed below:

Application Serial No.	Filing Date
60/233,586	9/18/2000
60/262,835	1/19/2001
60/303,751	7/6/2001

We hereby claim the benefit under 35 U.S.C. § 120 of the United States application(s), or § 365(c) of any PCT International application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior

United States or PCT International application in the manner provided by the first paragraph of 35 U.S.C. §112, I acknowledge the duty to disclose information which is material to patentability as defined in 37 C.F.R. § 1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application.

Application Serial No.	Filing Date	Status
		<input type="checkbox"/> Patented <input type="checkbox"/> Pending <input type="checkbox"/> Abandoned

We hereby declare that all statements made herein of our own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under § 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Date: 12/3/01 By: Charles A. Nicolette
Name: Charles A. Nicolette
Residence: 4 Mill Street, Framingham, MA 01701
Citizenship: USA
Post Office Address: 4 Mill Street, Framingham, MA 01701

Date: 12/3/01 By: Bruce L. Roberts
Name: Bruce L. Roberts
Residence: 108 Pinehill Road, Southborough, MA 01772
Citizenship: USA
Post Office Address: 108 Pinehill Road, Southborough, MA 01772

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application for:

Charles A. NICOLETTE, et al.

Serial No.: 09/955,656

Filing Date: September 18, 2001

For: METHOD TO IDENTIFY ANTIBODY
TARGETS

Examiner: Unassigned

Group Art Unit: 1645

PROSECUTION BY ASSIGNEE AND POWER OF ATTORNEY
UNDER 37 C.F.R. § 3.71Commissioner for Patents
Washington, D.C. 20231

Sir:

Genzyme Corporation, the assignee of the entire right, title and interest in this patent application, under 37 C.F.R. § 3.71 hereby appoints:

Attorney	Registration No.	Attorney	Registration No.
David Beck	37,776	John W. Calkins	43,523
Patricia R. Coleman James	37,155	Terry Garnett	44,698
Carol M. Gruppi	37,341	Antoinette F. Konski	34,202
David W. Maher	40,077	Michael J. Shuster	41,310
William E. Thomson, Jr.	20,719	Michele Todd Wasmuth	43,239
Michael E. Woods	33,466		

all of the firm McCutchen Doyle Brown & Enersen LLP, Three Embarcadero Center, Suite 1800, San Francisco, CA 94111-4067, to prosecute this application and transact all matters in the United States Patent and Trademark Office connected therewith, said appointment to be to the exclusion of the inventors and their attorneys in accordance with the provisions of 37 C.F.R. § 3.71.

The following persons are also appointed agents of record in the above-identified application:

Attorney	Registration No.
Richard D. Allison	31,584
Robert J. Cobert	36,108
Thomas J. DesRosier	30,168
Deborah A. Dugan	37,315
Jennifer L. Dupré	41,722
Madge R. Kanter	35,211
Elizabeth Lassen	31,845
Bart G. Newland	31,282
Jennifer A. Tegfeldt	31,310
Darlene Vanstone	35,729

Please direct all written communications relative to this application to:

Antoinette F. Konski
McCutchen Doyle Brown & Enersen LLP
Three Embarcadero Center, Suite 1800
San Francisco, CA 94111-4067

Please direct all telephone communications to Antoinette F. Konski at (650) 849-4950.

GENZYME CORPORATION

Dated: 12-04-01

By: 

Name: Thomas J. DesRosier
Title: Senior Vice President
Chief Patent Counsel
Address: One Kendall Square
Cambridge, MA 02139

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application for:

Charles A. NICOLETTE, et al.

Serial No.: 09/955,656

Filing Date: September 18, 2001

For: Method To Identify Antibody Targets

Examiner: Unassigned

Group Art Unit: 1645



CERTIFICATE UNDER 37 C.F.R. § 3.73(b)

Genzyme Corporation, a Massachusetts corporation certifies that it is the assignee of the entire right, title and interest in the patent application identified above by virtue of either:

A. An assignment from the inventors of the parent application identified above. The assignment is being filed under separate cover and a copy thereof is attached.

OR

B. A chain of title from the inventor(s), of the patent application identified above, to the current assignee as shown below:

1. From: * To: *

The document was recorded in the Patent and Trademark Office at Reel *, Frame *, or for which a copy thereof is attached.

2. From: * To: *

The document was recorded in the Patent and Trademark Office at Reel *, Frame *, or for which a copy thereof is attached.

3. From: * To: *

The document was recorded in the Patent and Trademark Office at Reel *, Frame *, or for which a copy thereof is attached.

Additional documents in the chain of title are listed on a supplemental sheet.

Copies of assignments or other documents in the chain of title are attached.

The undersigned has reviewed all the documents in the chain of title of the patent application identified above and, to the best of the undersigned's knowledge and belief, title is in the assignee identified above.

I hereby declare that all statements made herein of my own knowledge are true, and that all statements made on information and belief are believed to be true; and further, that these statements are made with the knowledge that willful false statements and the like so made, are punishable by fine or imprisonment, or both, under Section 1001, Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Dated: 12-04-01

By: 

Name: Thomas J. DesRosier
Title: Senior Vice President
Chief Patent Counsel
Address: Genzyme Corporation
One Kendall Square
Cambridge, MA 02139